Axogen earnings release, July 29, 2026

Axogen, Inc. (AXGN) · Form 8-K, Item 2.02 · Filed · SEC filing

Axogen, Inc. Reports Second Quarter 2026 Financial Results

Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million

ALACHUA and TAMPA, FL – July 29, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2026.

Second Quarter Financial Results

• Revenue was $69.7 million, an increase of 23.1% compared with $56.7 million in the second quarter of 2025.

• Gross margin was 72.7% compared to 74.2% in the second quarter of 2025. Gross margin performance was driven by changes in product mix caused primarily by accelerating year over year Breast growth greater than 50%.

• Net loss was $1.5 million, or $0.03 per share, compared to a Net income of $0.6 million, or $0.01 per share for the second quarter of 2025.

• Adjusted net income was $7.3 million, or $0.12 per share, as compared to $5.7 million, or $0.12 per share for the second quarter of 2025.

• Adjusted EBITDA was $8.4 million, compared to $9.3 million for the second quarter of 2025.

• Cash and cash equivalents, restricted cash, and investments as of June 30, 2026 was $113.4 million, as compared to $103.6 million as of March 31, 2026, an increase of $9.8 million.

“We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities,” said Michael Dale, President and CEO of Axogen, Inc. “Our strong growth across all our target markets, continues to reinforce the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our revenue guidance and continue advancing our strategic objectives for 2026.”

Summary of Business Highlights

• Year-to-date revenue growth through the second quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast, driven by 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment.

• Publication of REPOSE, a prospective, randomized clinical study evaluating Axoguard Nerve Cap for symptomatic neuroma management, providing Level 1 evidence supporting nerve end protection and demonstrating favorable outcomes in pain burden, medication utilization, and recovery-related measures.

• Initiated Nerve-RESTORE, a prospective, randomized, assessor-blinded study comparing Avance Nerve Graft to sural nerve autograft in mixed and motor nerve reconstruction, designed to generate Level 1 evidence supporting broader adoption of nerve repair globally.

• Acquired a minority ownership stake in Trace Biosciences, including a limited right of first refusal, to support development of its nerve-specific imaging technology.

2026 Financial Guidance

For 2026, we expect full-year revenue growth to be at least 24%, or revenue of at least $279 million, gross margin to be at least 73%, and positive free cash flow for the full-year.

Conference Call

The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the Company’s website at www.axogeninc.com under Investors.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen’s product portfolio includes Avance®

(acellular nerve allograft-arwx), Avance®

Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

For more information, visit www.axogeninc.com.

Financial statements

Income Statement

Three Months Ended — (in thousands, except share and per share amounts)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Six Months Ended – June 30, 2026Six Months Ended – June 30, 2025
Revenues69,73156,662131,188105,222
Cost of goods sold19,05714,64434,32528,271
Gross profit50,67442,01896,86376,951
Costs and expenses:Sales and marketing30,82723,80459,46044,849
Costs and expenses:Research and development8,5896,85316,10612,944
Costs and expenses:General and administrative13,4149,68926,28519,147
Costs and expenses:Total costs and expenses52,83040,346101,85176,940
Costs and expenses:(Loss) income from operations-2,1561,672-4,98811
Other income (expense):Investment income7862251,554497
Other income (expense):Interest expense-1-1,977-695-4,227
Other income (expense):Loss on extinguishment of debt-16,849
Other income (expense):Change in fair value of debt derivative liabilities480322
Other income (expense):Other (expense) income, net-145179-122142
Other income (expense):Total other income (expense), net640-1,093-16,112-3,266
Other income (expense):Net (loss) income-1,516579-21,100-3,255
Other income (expense):Weighted average common shares outstanding — basic53,339,25846,063,09252,562,97645,605,419
Other income (expense):Weighted average common shares outstanding — diluted53,339,25847,980,83052,562,97645,605,419
Other income (expense):Net (loss) income per common share — basic-0.030.01-0.4-0.07
Other income (expense):Net (loss) income per common share — diluted-0.030.01-0.4-0.07

Income Statement

Common Stock — (in thousands, except share amounts)

Common Stock – SharesCommon Stock – AmountAdditional Paid-in CapitalAccumulated DeficitTotal Shareholders' Equity
Three Months Ended June 30, 2026Balance at March 31, 202653,153,471532570,823-326,547244,808
Three Months Ended June 30, 2026Net loss-1,516-1,516
Three Months Ended June 30, 2026Stock-based compensation8,7668,766
Three Months Ended June 30, 2026Issuance of restricted and performance stock units, net of shares withheld for withholding taxes134,8921-498-497
Three Months Ended June 30, 2026Exercise of stock options and employee stock purchases under the ESPP367,93044,6924,696
Three Months Ended June 30, 2026Balance at June 30, 202653,656,293537583,783-328,063256,257
Six Months Ended June 30, 2026Balance at December 31, 202547,199,797472435,338-306,963128,847
Six Months Ended June 30, 2026Net loss-21,100-21,100
Six Months Ended June 30, 2026Issuance of common shares4,600,00046133,206133,252
Six Months Ended June 30, 2026Stock-based compensation15,60915,609
Six Months Ended June 30, 2026Issuance of restricted and performance stock units, net of shares withheld for withholding taxes1,120,68811-9,284-9,273
Six Months Ended June 30, 2026Exercise of stock options and employee stock purchases under the ESPP735,80888,9148,922
Six Months Ended June 30, 2026Balance at June 30, 202653,656,293537583,783-328,063256,257
Three Months Ended June 30, 2025Balance at December 31, 202445,512,623455400,004-295,094105,365
Three Months Ended June 30, 2025Net income579579
Three Months Ended June 30, 2025Stock-based compensation5,1685,168
Three Months Ended June 30, 2025Issuance of restricted and performance stock units113,9231-1
Three Months Ended June 30, 2025Exercise of stock options and employee stock purchases under the ESPP138,74411,1631,164
Three Months Ended June 30, 2025Balance at June 30, 202545,765,290457406,334-294,515112,276
Six Months Ended June 30, 2025Balance at December 31, 202444,148,836441394,726-291,260103,907
Six Months Ended June 30, 2025Net loss-3,255-3,255
Six Months Ended June 30, 2025Stock-based compensation8,0778,077
Six Months Ended June 30, 2025Issuance of restricted and performance stock units1,219,13712-12
Six Months Ended June 30, 2025Exercise of stock options and employee stock purchases under the ESPP397,31743,5433,547
Six Months Ended June 30, 2025Balance at June 30, 202545,765,290457406,334-294,515112,276

Income Statement

EBITDA & Adjusted EBITDA — (in thousands, except share and per share amounts)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Six Months Ended – June 30, 2026Six Months Ended – June 30, 2025
Net (loss) income-1,516579-21,100-3,255
Depreciation and amortization expense1,7171,7233,4223,518
Investment income-786-225-1,554-497
Income tax expense2213718866
Interest expense11,9776954,227
EBITDA - non-GAAP-3634,091-18,3494,059
EBITDA margin - non-GAAP-0.57.2-143.9
Non-cash stock-based compensation expense8,7665,16815,6098,077
Loss on extinguishment of debt16,849
Adjusted EBITDA - non-GAAP8,4039,25914,10912,136
Adjusted EBITDA margin - non-GAAP12.116.310.811.5

Income Statement

Adjusted Net Income — (in thousands, except share and per share amounts)

GAAP ResultsNon-cash Stock-based Compensation ExpenseAdjusted Results
RevenuesGAAP Results56,662Non-cash Stock-based Compensation ExpenseAdjusted Results56,662
Cost of goods sold14,644-71013,934
Gross profit42,01871042,728
Costs and expenses:Sales and marketing23,804-1,31422,490
Costs and expenses:Research and development6,853-1,0295,824
Costs and expenses:General and administrative9,689-2,1157,574
Costs and expenses:Total costs and expenses40,346-4,45835,888
Costs and expenses:Income from operations1,6725,1686,840
Other income (expense):Investment income225225
Other income (expense):Interest expense-1,977-1,977
Other income (expense):Change in fair value of debt derivative liabilities480480
Other income (expense):Other income, net179179
Other income (expense):Total other expense, net-1,093-1,093
Other income (expense):Net income5795,1685,747
Other income (expense):Weighted average common shares outstanding - diluted47,980,83047,980,83047,980,830
Other income (expense):Net income per common share - diluted0.010.110.12

Income Statement

Adjusted Net Income — (in thousands, except share and per share amounts)

Six Months Ended June 30, 2026 – GAAP ResultsSix Months Ended June 30, 2026Six Months Ended June 30, 2026 – Non-cash Stock-based Compensation ExpenseSix Months Ended June 30, 2026 – Loss on Extinguishment of DebtSix Months Ended June 30, 2026 – Dilutive Shares Impact(1)Six Months Ended June 30, 2026 – Adjusted Results
RevenuesGAAP Results131,188Non-cash Stock-based Compensation ExpenseLoss on Extinguishment of DebtAdjusted Results131,188
Cost of goods sold34,325-2,12932,196
Gross profit96,8632,12998,992
Costs and expenses:Sales and marketing59,460-3,56155,899
Costs and expenses:Research and development16,106-3,21412,892
Costs and expenses:General and administrative26,285-6,70519,580
Costs and expenses:Total costs and expenses101,851-13,48088,371
Costs and expenses:(Loss) income from operations-4,98815,60910,621
Other income (expense):Investment income1,5541,554
Other income (expense):Interest expense-695-695
Other income (expense):Loss on extinguishment of debt-16,84916,849
Other income (expense):Other expense, net-122-122
Other income (expense):Total other (expense) income, net-16,11216,849737
Other income (expense):Net (loss) income-21,10015,60916,84911,358
Other income (expense):Weighted average common shares outstanding - diluted52,562,97652,562,97652,562,9765,966,87758,529,853
Other income (expense):Net (loss) income per common share - diluted-0.40.30.32-0.020.19

Income Statement

Adjusted Net Income — (in thousands, except share and per share amounts)

GAAP ResultsNon-cash Stock-based Compensation ExpenseDilutive Shares Impact(1)Adjusted Results
RevenuesGAAP Results105,222Non-cash Stock-based Compensation ExpenseAdjusted Results105,222
Cost of goods sold28,271-70027,571
Gross profit76,95170077,651
Costs and expenses:Sales and marketing44,849-1,89842,951
Costs and expenses:Research and development12,944-1,74911,195
Costs and expenses:General and administrative19,147-3,73015,417
Costs and expenses:Total costs and expenses76,940-7,37769,563
Costs and expenses:Income from operations118,0778,088
Other income (expense):Investment income497497
Other income (expense):Interest expense-4,227-4,227
Other income (expense):Change in fair value of debt derivative liabilities322322
Other income (expense):Other income, net142142
Other income (expense):Total other expense, net-3,266-3,266
Other income (expense):Net (loss) income-3,2558,0774,822
Other income (expense):Weighted average common shares outstanding - diluted45,605,41945,605,4192,650,57648,255,995

Balance Sheet

(in thousands, except share and per share amounts)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents94,57235,548
Current assets:Restricted cash2,0004,000
Current assets:Investments16,8405,980
Current assets:Accounts receivable, net of allowance for doubtful accounts of $734 and $948, respectively34,12626,169
Current assets:Inventory47,31342,373
Current assets:Prepaid expenses and other assets5,5256,352
Current assets:Total current assets200,376120,422
Current assets:Property and equipment, net82,34281,783
Current assets:Operating lease right-of-use assets13,84512,732
Current assets:Intangible assets, net7,5716,750
Current assets:Other assets729
Current assets:Total assets304,863221,687
Current liabilities:Accounts payable and accrued expenses28,39921,184
Current liabilities:Current maturities of long-term lease obligations1,9752,372
Current liabilities:Total current liabilities30,37423,556
Current liabilities:Long-term debt, net of debt discount and financing fees48,387
Current liabilities:Long-term lease obligations18,09116,870
Current liabilities:Debt derivative liabilities3,886
Current liabilities:Other long-term liabilities141141
Current liabilities:Total liabilities48,60692,840
Shareholders’ equity:Common stock, $0.01 par value per share; 100,000,000 shares authorized; 53,656,293 and 47,199,797 shares issued and outstanding, respectively537472
Shareholders’ equity:Additional paid-in capital583,783435,338
Shareholders’ equity:Accumulated deficit-328,063-306,963
Shareholders’ equity:Total shareholders’ equity256,257128,847
Shareholders’ equity:Total liabilities and shareholders’ equity304,863221,687

Cash Flow

Six Months Ended — (in thousands)

Six Months Ended – June 30, 2026Six Months Ended – June 30, 2025
Cash flows from operating activities:Net loss-21,100-3,255
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation3,2113,385
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of right-of-use assets854184
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of intangible assets212133
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of debt discount and deferred financing fees68442
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:(Recovery of) provision for bad debts-52386
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Loss on disposal of equipment7
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Change in fair value of debt derivative liabilities-322
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Investment gains, net-110-121
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Loss on extinguishment of debt16,849
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation expense15,6098,077
Change in operating assets and liabilities:Accounts receivable-7,905-4,310
Change in operating assets and liabilities:Inventory-4,940-3,591
Change in operating assets and liabilities:Prepaid expenses and other assets827-81
Change in operating assets and liabilities:Other assets-729
Change in operating assets and liabilities:Accounts payable and accrued expenses7,118-5,755
Change in operating assets and liabilities:Operating lease obligations-1,130-542
Change in operating assets and liabilities:Cash paid for interest portion of financing lease obligations-3-2
Change in operating assets and liabilities:Other long-term liabilities-77
Change in operating assets and liabilities:Net cash provided by (used in) operating activities8,786-5,449
Cash flows from investing activities:Purchase of property and equipment-3,682-978
Cash flows from investing activities:Purchase of investments-18,750-7,837
Cash flows from investing activities:Proceeds from sale of investments8,0004,000
Cash flows from investing activities:Cash payments for intangible assets-1,032-793
Cash flows from investing activities:Net cash used in investing activities-15,464-5,608
Cash flows from financing activities:Proceeds from issuance of common stock134,044
Cash flows from financing activities:Payment of stock issuance costs-792
Cash flows from financing activities:Repayment of long-term debt-48,585
Cash flows from financing activities:Fees paid to lender related to debt extinguishment-20,498
Cash flows from financing activities:Fees paid to third parties related to debt extinguishment-107
Cash flows from financing activities:Payments of employee tax withholding on vested stock awards-9,273
Cash flows from financing activities:Cash paid for debt portion of financing lease obligations-9-8
Cash flows from financing activities:Proceeds from exercise of stock options and ESPP stock purchases8,9223,547
Cash flows from financing activities:Net cash provided by financing activities63,7023,539
Cash flows from financing activities:Net increase (decrease) in cash and cash equivalents, and restricted cash57,024-7,518
Cash flows from financing activities:Cash and cash equivalents, and restricted cash, beginning of period39,54833,554

Cash Flow

Free Cash Flow

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net cash provided by (used in) operating activities8,786-5,449
Purchase of property and equipment-3,682-978
Cash payments for intangible assets-1,032-793
Free cash flow4,072-7,220
Full release

Cautionary Statements Concerning Forward-Looking Statements... (truncated)eks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or events could differ materially from those described in any forward-looking statements as a result of factors, including, without limitation, disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon adoption rates, market awareness of our products, the estimated total addressable market, as well as those risk factors described under Part I, Item 1A, “Risk Factors,” in our most recent Annual Report on Form 10-K and other risks and uncertainties that may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further excludes non-cash stock-based compensation expense and the loss on extinguishment of debt, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income and Adjusted Net Income Per Common Share - diluted which excludes non-cash stock-based compensation expense and the loss on extinguishment of debt from Net (Loss) Income and Net (Loss) Income Per Common Share - diluted. Additionally, we use the non-GAAP financial measure of Free Cash Flow which consists of net cash provided by operating activities, less expenditures for property and equipment, and intangible assets.

These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

Axogen, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

Axogen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)

Axogen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

Axogen, Inc.

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(unaudited)

(in thousands, except share amounts)

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

__________

(1)

Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

__________

(1)

Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

Axogen, Inc.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(unaudited)

(in thousands, except share and per share amounts)

__________

(1)

Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Axogen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.